
Swabhi Pharma Private Limited
About Swabhi Pharma Private Limited
Data last updated:
Swabhi Pharma Private Limited is a private limited company based in Delhi, India. It operates in the medicinal chemical and botanical products segment of the chemicals sector. It was incorporated on 07 September 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U51909DL2016PTC305582. The company has 1 GST registration on record, which is no longer active.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Swati Shrivastava and Abhishek Shrivastava.
Its last annual general meeting (AGM) was held on 30 September 2022, and its latest financial statements are for the year ended 31 March 2022. The registered office is at #60 Fourth Floor Krishan Kunj Colony Laxmi Nagar, Delhi, India – 110092.
As per the financials filed for FY 2022, the company reported a revenue of ₹11.2 Lakh, a growth of 64% compared to the previous year. For the same year it recorded a net profit of ₹64,383 (net margin 5.7%) and EBITDA of ₹64,383 (EBITDA margin 5.7%). Revenue has declined at a compounded annual rate (CAGR) of 1% over three years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Swabhi Pharma Private Limited's registered office is in Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address#60 Fourth Floor Krishan Kunj Colony Laxmi Nagar, Delhi, India – 110092
- IndustryChemicals, Medicinal Chemical & Botanical Products, Pharmaceuticals, Chemical Products
To see the full contact details of Swabhi Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Swabhi Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Swabhi Pharma Private Limited, buy the company report.
Financials of Swabhi Pharma Private Limited
FY 2022 filings availableSwabhi Pharma Private Limited reported revenue of ₹11.2 Lakh (up 64% YoY) for FY 2022.
Compounded Annual Growth Rate (CAGR)
Revenue rose 64% in the latest year, though over three years it has declined at a compounded annual rate (CAGR) of 1%. EBITDA rose 183% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹64,383 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹64,383 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.7% | ||||
| Net Profit Margin | 5.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Swabhi Pharma Private Limited, buy the company report.
Board of directors of Swabhi Pharma Private Limited
Swabhi Pharma has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Swati Shrivastava | Director | 07 Sep 2016 | 10 Years 1 Months | Current |
| Abhishek Shrivastava | Director | 07 Sep 2016 | 10 Years 1 Months | Current |
Peer comparison
Swabhi Pharma Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Tejika Labs Private Limited | ₹11.25 Lakh (FY 2023) | 46.0% | Ankleshwar, Gujarat, India | |||
| Resalutem Pharmaceutical Private Limited | ₹11.22 Lakh (FY 2020) | 184.0% | Surat, Gujarat, India | |||
| Alible Pharmaceutical Private Limited | ₹11.22 Lakh (FY 2025) | 10.0% | Thane, Maharashtra, India | |||
| Mahija Biofuel Industries Private Limited | ₹11.21 Lakh (FY 2023) | Ahmedabad, Gujarat, India | ||||
| Ignis Control Systems Private Limited | ₹11.2 Lakh (FY 2022) | 254.0% | Bangalore, Karnataka, India | |||
| Swabhi Pharma Private Limitedthis company | ₹11.2 Lakh (FY 2022) | ₹64,383 | 5.7% | 64.0% | Delhi, India | |
| Ashoka Biotech Private Limited | ₹11.18 Lakh (FY 2023) | 107536250.0% | Bangalore, Karnataka, India | |||
| Arm Bioorganic Private Limited | ₹11.18 Lakh (FY 2019) | 154.0% | Vadodara, Gujarat, India | |||
| Dna Technologies Private Limited | ₹11.17 Lakh (FY 2024) | 73.0% | Uttar Pradesh, India | |||
| R D Home Products (OPC) Private Limited | ₹11.15 Lakh (FY 2021) | -47.0% | Nalagarh, Himachal Pradesh, India | |||
| Solbritt Chemsynth Private Limited | ₹11.15 Lakh (FY 2023) | Vadodara, Gujarat, India |
To see the full peer comparison of Swabhi Pharma Private Limited, buy the company report.
Auditor
Swabhi Pharma Private Limited is audited by Ankur Kamra and Company for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Ankur Kamra and Company | FY 2017 | 514730 |
Shareholding
The shareholding of Swabhi Pharma Private Limited is on record for FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Foreign institutional investors (FII) | |
| Public | |
| Others |
To see the full shareholding pattern of Swabhi Pharma Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Swabhi Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Swabhi Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Swabhi Pharma has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of Swabhi Pharma Private Limited, buy the company report.
Recent activity
Swabhi Pharma Private Limited has 2 board changes on record since 2016: 2 appointments. The latest: Abhishek Shrivastava was appointed as Director on 07 Sep 2016.
Frequently asked questions
Swabhi Pharma is an active private limited company based in Delhi, India. The company works in medicinal chemical and botanical products, within the chemicals industry. It was incorporated on 07 September 2016 (10+ years old) and is registered under CIN U51909DL2016PTC305582.
Swabhi Pharma has 2 current directors:
- Swati Shrivastava - Director
- Abhishek Shrivastava - Director
The latest financial statements of Swabhi Pharma on record with the MCA are for the year ended 31 March 2022. Its last annual general meeting was held on 30 September 2022. Year-wise statements from FY 2017 are in the company report.
No. Swabhi Pharma has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Swabhi Pharma is U51909DL2016PTC305582. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Swabhi Pharma was incorporated on 07 September 2016, making it 10+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Swabhi Pharma by revenue are Tejika Labs Private Limited, Resalutem Pharmaceutical Private Limited, Alible Pharmaceutical Private Limited, Mahija Biofuel Industries Private Limited, Ignis Control Systems Private Limited and 5 more, all in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Abhishek Shrivastava was appointed as Director on 07 Sep 2016. Swati Shrivastava was appointed as Director on 07 Sep 2016.
The registered office of Swabhi Pharma is at #60 Fourth Floor Krishan Kunj Colony Laxmi Nagar, Delhi, India – 110092.
Swabhi Pharma operates in the chemicals industry, in the medicinal chemical and botanical products segment.
The compliance status of Swabhi Pharma is compliant as of 23 September 2026. The company is actively filing with the Registrar of Companies.

